Supriya Lifescience Limited
NSE: SUPRIYA.NS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- National Stock Exchange of India
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Satish Waman Wagh
- Employees
- 448
- Headquarters
- Mumbai, India
- IPO year
- 2021
- Market cap
- ₹56.9B
- Website
- https://www.supriyalifescience.com
Loading SUPRIYA…
Loading profile data…Frequently asked questions about SUPRIYA
What does Supriya Lifescience Limited (SUPRIYA.NS) do?
Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, a...
Where does SUPRIYA.NS trade?
Supriya Lifescience Limited (SUPRIYA.NS) trades on the National Stock Exchange of India.
What sector is SUPRIYA.NS in?
Supriya Lifescience Limited (SUPRIYA.NS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Supriya Lifescience Limited?
Satish Waman Wagh is the chief executive officer of Supriya Lifescience Limited (SUPRIYA.NS).
Where is Supriya Lifescience Limited headquartered?
Supriya Lifescience Limited is headquartered in India.
Does SUPRIYA.NS pay a dividend?
Yes — Supriya Lifescience Limited (SUPRIYA.NS) paid a trailing twelve-month dividend of INR 1.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did SUPRIYA.NS go public?
Supriya Lifescience Limited (SUPRIYA.NS) completed its initial public offering in 2021.